health
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
TL;DR
- At least five Indian drugmakers have launched generic versions of Novo Nordisk's GLP-1 weight-loss drugs, with prices up to 80% lower than the original.
- The patent expiration in India allows for this increased competition in a market with a high prevalence of diabetes and obesity.
- Sun Pharmaceutical and Dr. Reddy's Laboratories are among the major players launching generic semaglutide, aiming to democratize access to these drugs.
- Novo Nordisk is banking on its brand reputation, technology, and established partnerships to retain users and market share, despite the price reductions and competition.
- Challenges for Indian generics include the complex peptide-based nature of GLP-1 drugs, requiring stringent quality control and specialized manufacturing processes.
- Analysts suggest Novo Nordisk may need further price cuts in India to maintain its market share, though the company is confident in its value proposition.
- The growing Indian market for GLP-1 drugs has seen rapid sales increases, but high prices remain a barrier for many patients.